NEWRON PHARMACEUT. EO-20

Research NEWRON PHARMACEUT. EO-20 (NP5) on Bullrun: market cap EUR 281.92M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerNP5
• ExchangeXETRA
• CountryItaly
• SectorHealthcare
• IndustryBiotechnology
• CurrencyEUR
• Market capEUR 281.92M
• Financial periodFY2025
• RevenueEUR 19.13M
• Revenue growth-62.8%
• Net income-EUR 13.24M
• Free cash flowEUR 32.30M

Valuation Snapshot

latest market cap is EUR 281.92M.

About NEWRON PHARMACEUT. EO-20

Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan.

Frequently asked questions

What is NEWRON PHARMACEUT. EO-20's market cap?

NEWRON PHARMACEUT. EO-20's market capitalization is EUR 281.92M.

What does NEWRON PHARMACEUT. EO-20 do?

Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States.